• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    AavantiBio Further Enhances Leadership Team with Appointment of Jenny Marlowe, Ph.D. as Chief Scientific Officer

    11/16/21 8:00:00 AM ET
    $BLUE
    $NVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BLUE alert in real time by email

    AavantiBio ("the Company"), a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Jenny Marlowe, Ph.D. as Chief Scientific Officer. Dr. Marlowe will be responsible for leading AavantiBio's scientific research and preclinical development. She will also serve as a key member of the company's executive leadership team as AavantiBio seeks to advance its diversified pipeline of gene therapies in areas of significant unmet medical need.

    Dr. Marlowe brings to AavantiBio nearly 15 years of experience in the biopharmaceutical industry, including extensive experience in molecular biology, drug safety, and nonclinical and translational development. She joins from Bluebird Bio Inc. (NASDAQ:BLUE) where she previously served as Vice President of Preclinical & Translational Development, with responsibilities for preclinical development and translational biomarker strategies for the company's portfolio of cell and gene therapies for both oncology and rare disease. She played a critical role in the success of several key regulatory submissions, including most recently a Biologics License Application for betibeglogene autotemcel for beta-Thalassemia, an inherited blood disorder.

    "We are delighted to have Jenny join the AavantiBio team and expand our scientific and early-stage development capabilities. She brings a wealth of leadership and expertise in research, toxicology, and investigation of gene therapies and shares our commitment to serving patients with rare genetic diseases," said Bo Cumbo, President and Chief Executive Officer of AavantiBio. "Jenny's deep experience in the development of cell and gene therapies further bolsters our ability to advance our growing pipeline of gene therapy programs and platform capabilities, and we look forward to benefiting from her scientific, development, and strategic insight."

    "I am excited to join a company and management team that shares my passion for and commitment to scientific rigor and innovation," said Dr. Marlowe. "I look forward to working closely with this dynamic and experienced team and supporting AavantiBio's mission of bringing multiple groundbreaking genetic therapies to more patients."

    Dr. Marlowe began her career at Novartis (NYSE:NVS), where she held positions of increasing responsibility within the company's Investigative Toxicology and Preclinical Safety functions, including directing projects across a broad portfolio of indications and drug modalities. Prior to joining Novartis, Dr. Marlowe earned a PhD in Molecular Toxicology from the Department of Environmental Health Sciences at the University of Cincinnati. She also holds a Bachelor of Science degree in Zoology from Miami University.

    Since launching in 2020 with foundational financial backing from some of the life science industry's leading investors, AavantiBio has made significant progress building out the Company's strategic and development capabilities. The Company has also announced strategic partnerships and collaborations with Aldveron, National Resilience, Inc., Catalent, and the University of Florida in recent months to support the development and manufacturing of a diversified pipeline of gene therapies.

    About AavantiBio, Inc.

    AavantiBio is a gene therapy company backed by a premier syndicate of life sciences investors including Perceptive Advisors, Bain Capital Life Sciences, and RA Capital Management, who led the company's $107 million Series A financing. Headquartered in Cambridge, Massachusetts, AavantiBio's platform is focused on advancing innovative gene therapies in areas of high unmet medical need, including a lead program in Friedreich's Ataxia, a rare inherited genetic disease that causes cardiac and central nervous system dysfunction. The company benefits from strategic partnerships with the University of Florida's Powell Gene Therapy Center and the MDA Care Center at UF Health where AavantiBio's co-founders and renowned gene therapy researchers Barry Byrne, M.D., Ph.D. and Manuela Corti, P.T., Ph.D. maintain their research and clinical practices. Learn more at www.aavantibio.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005232/en/

    Get the next $BLUE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLUE
    $NVS

    CompanyDatePrice TargetRatingAnalyst
    bluebird bio Inc.
    $BLUE
    2/24/2025Underweight → Neutral
    Analyst
    bluebird bio Inc.
    $BLUE
    2/24/2025$29.00Overweight
    Analyst
    Novartis AG
    $NVS
    2/13/2025Buy → Neutral
    UBS
    Novartis AG
    $NVS
    2/12/2025Underweight
    Morgan Stanley
    Novartis AG
    $NVS
    2/4/2025Hold → Buy
    Deutsche Bank
    Novartis AG
    $NVS
    12/4/2024Hold → Reduce
    HSBC Securities
    bluebird bio Inc.
    $BLUE
    11/18/2024Neutral → Underweight
    Analyst
    bluebird bio Inc.
    $BLUE
    11/15/2024Neutral → Underweight
    JP Morgan
    More analyst ratings

    $BLUE
    $NVS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital

      bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird") today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tender offer by Carlyle and SK Capital to purchase all outstanding shares of bluebird common stock by 11:59 p.m. Eastern on May 12, 2025. Stockholders that hold shares of bluebird common stock through a broker or other nominee may be subject to a processing cutoff that is prior to the tender deadline, so it is important to act now. Every share tendered by stockholders is important and it is important to tender now. If a majority of the outstanding shares of bluebird common stock are not tendered, the tender offer will not be completed, a

      5/9/25 8:30:00 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio

      bluebird Board of Directors unanimously supports the transaction as the only viable option for stockholders to receive consideration for their shares and recommends that all stockholders immediately tender their shares into the offer Parties expect the merger to be completed promptly following the successful completion of the ongoing tender offer bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird" or "the Company"), Carlyle (NASDAQ:CG) ("Carlyle"), SK Capital Partners, LP ("SK Capital") and Beacon Parent Holdings, L.P. ("Parent") announced today that all required regulatory approvals to complete the previously announced acquisition of the Company by Carlyle and SK Capital have been received. No

      5/5/25 4:00:00 PM ET
      $BLUE
      $CG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Investment Managers
      Finance
    • bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement

      bluebird Board reaffirms unanimous recommendation in support of transaction with Carlyle and SK Capital and recommends all stockholders tender into the current agreement by May 2, 2025 bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird" or "the Company") today announced that after three weeks of engagement, including a timeline extension, Ayrmid Ltd. ("Ayrmid") has not submitted a binding proposal to acquire bluebird and has not obtained necessary financing. In consultation with its financial and legal advisors, the bluebird Board of Directors (the "Board") reaffirms its recommendation in support of the transaction with Carlyle and SK Capital and recommends all stockholders tender into the curren

      4/16/25 8:00:00 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    $NVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Colvin Richard A sold $2,289 worth of shares (584 units at $3.92), decreasing direct ownership by 7% to 7,610 units (SEC Form 4)

      4 - bluebird bio, Inc. (0001293971) (Issuer)

      3/5/25 4:05:53 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Klima Thomas J sold $1,960 worth of shares (500 units at $3.92), decreasing direct ownership by 6% to 7,878 units (SEC Form 4)

      4 - bluebird bio, Inc. (0001293971) (Issuer)

      3/5/25 4:05:41 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Obenshain Andrew sold $3,610 worth of shares (921 units at $3.92), decreasing direct ownership by 5% to 18,327 units (SEC Form 4)

      4 - bluebird bio, Inc. (0001293971) (Issuer)

      3/5/25 4:05:24 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    $NVS
    Financials

    Live finance-specific insights

    See more
    • PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

      - PTC to receive $1.0B in cash at closing -- PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones -- PTC to share profits in the U.S. and tiered double-digit royalties on ex-U.S. net sales -- Novartis will assume global development, manufacturing and commercial responsibilities following completion of placebo-controlled portion of ongoing PIVOT-HD study -- PTC will host a conference call on Dec. 2, 2024, at 8:30 am EST- WARREN, N.J., Dec. 2, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NY

      12/2/24 7:00:00 AM ET
      $NVS
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

      - 74 patient starts completed or scheduled to date in 2024 across bluebird's commercial portfolio - - Third quarter 2024 net revenue of $10.6 million reflects quarter-to-quarter fluctuations in drug product infusions; anticipate at least $25 million of net revenue in the fourth quarter - - Management to host conference call today, November 14, 2024 at 8:00 am ET - bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September 30, 2024, including recent commercial and operational progress. "Patient starts more than doubled from our second to third quarter update, providing clear evidence

      11/14/24 7:00:00 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call

      bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today announced that it partially adjourned its annual meeting of stockholders ("Annual Meeting") on Wednesday, November 6, 2024, to allow the Company to solicit additional votes to obtain approval of Proposal 4, a reverse stock split, as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on September 26, 2024 (the "proxy statement"). The Company's stockholders approved Proposals 1, 2, 5, 6 and 7, and did not approve Proposal 3 during the Annual Meeting held earlier today (all proposals as described in the proxy statement). The Annual Meeting will reconvene on December 4,

      11/6/24 4:15:00 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    $NVS
    SEC Filings

    See more
    • Amendment: SEC Form SC 14D9/A filed by bluebird bio Inc.

      SC 14D9/A - bluebird bio, Inc. (0001293971) (Subject)

      5/9/25 8:44:57 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 14D9/A filed by bluebird bio Inc.

      SC 14D9/A - bluebird bio, Inc. (0001293971) (Subject)

      5/6/25 7:47:43 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC TO-T/A filed by bluebird bio Inc.

      SC TO-T/A - bluebird bio, Inc. (0001293971) (Subject)

      5/6/25 7:33:39 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    $NVS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 1, 2024 - FDA Roundup: November 1, 2024

      For Immediate Release: November 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “FDA Takes Exciting Steps Toward Establishing the Rare Disease Innovation Hub,” by Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research (CDER) and Peter Marks, M.D., Ph.D., director

      11/1/24 3:18:19 PM ET
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

      For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

      12/8/23 11:12:21 AM ET
      $BLUE
      $VRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • August 17, 2022 - FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions

      For Immediate Release: August 17, 2022 Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.  “Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing

      8/17/22 2:12:27 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    $NVS
    Leadership Updates

    Live Leadership Updates

    See more

    $BLUE
    $NVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components
    • PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

      11/5/24 7:05:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

      11/5/24 7:00:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Bluebirdbio upgraded by Analyst

      Analyst upgraded Bluebirdbio from Underweight to Neutral

      2/24/25 7:05:14 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Analyst initiated coverage on Bluebirdbio with a new price target

      Analyst initiated coverage of Bluebirdbio with a rating of Overweight and set a new price target of $29.00

      2/24/25 7:04:33 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novartis AG downgraded by UBS

      UBS downgraded Novartis AG from Buy to Neutral

      2/13/25 8:48:14 AM ET
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLUE
    $NVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

      SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

      11/14/24 4:39:36 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

      SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

      11/14/24 4:27:32 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

      SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

      11/14/24 10:32:08 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care